You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

125 Results
Guidelines and Advice
Status: Archived
ID: CED 1
Jun 2005
Guidelines and Advice
Status: Current
ID: MOTAC-7
Updated
Jan 2025
Guidelines and Advice
Status: Archived
ID: 12-4
Apr 2005
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-3
Updated
Mar 2025
Statistical Reports
Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....
New
Feb 2025
Guidelines and Advice
Status: Current
Updated
Mar 2025
Guidelines and Advice
Status: Current
ID: GL 17-10 v2
Version: 2
Updated
Mar 2025
Guidelines and Advice
Status: Archived
ID: 13-7
Feb 2005
Guidelines and Advice
Status: Archived
ID: 2-20-2
Sep 2005
Guidelines and Advice
Status: Archived
ID: 14-3
Jul 2005
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Maintenance Treatment for Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
avelumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025

Pages